Discovery to Cure is a site for the development of the latest clinical trials and new treatments. An ongoing collaboration and unique partnership between Discovery to Cure and more than ten pharmaceutical companies, the National Institute of Health, and the Yale Gynecologic Oncology Group provides the opportunity for Yale to secure trials for the study of new compounds to be used for treatment and new techniques for diagnosis.
Current clinical trials:
- Randomized Phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel of CT-2103 (IND#70177) vs. no treatment until documented relapse in women with advanced ovarian, primary peritoneal or fallopian tube cancer.
- Multicenter, randomized, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo, plus carboplatin and paclitaxel in patients with advanced ovarian cancer.
- A Phase III open label, randomized, two-arm study of Ixabepilone administered every 21 days versus Paclitaxel or Doxorubicin administered every 21 days in women with advanced endometrial cancer who have previously been treated with chemotherapy.
- A randomized double-blind, placebo controlled, multi-center, Phase II study of adding a fully-human monoclonal antibody against insulin-like growth factor 1 receptor (IGF-1R) to first-line chemotherapy in patients with optimally debulked (, 1cm) epithelial ovarian cancer.
- A Phase III trial of Paclitaxel/Carboplatin versus Ifosfamide/Paclitaxel in chemotherapy-naive patients with newly diagnosed Stage I-IV persistent or recurrent carcino sarcoma (mixed mesodermal tumors) of the uterus.
- Phase III trial of pelvic XRT versus vaginal cuff brachytherapy followed by Paclitaxel/Carboplatin in patients with high-risk, early stage endometrial cancer.
- Randomized Phase III trial of Cisplatin and tumor volume directed XRT followed by Carboplatin/Taxol versus Carboplatin/Taxol for optimally debulked, advanced endometrial carcinoma (Stage III or IV).
- Acquisition of human gynecologic specimens to be used in studying the causes, diagnosis, prevention and treatment of cancer.
- A non-interventional prospective study of the correlation of the Precision Therapeutics, Inc. ChemoResponse Assay with progression-free survival in patients with recurrent epithelial ovarian, peritoneal or fallopian tube cancer.